Skip Ribbon Commands
Skip to main content
  • Prof.  Hanna Rosenmann
Prof Hanna Rosenmann
Alzheimer's disease and other dementias - developing novel therapeutic approaches
Research in my lab focuses on therapies for Alzheimer's disease (AD) and other dementias (such as frontotemporal dementia). For this purpose we generated novel mouse models, which mimic authentically the diseases in the dementia patients.  Using the animal models we are developing therapeutic approaches, at the cutting edge of the AD research. This includes:
  1. Developing a vaccine which clears the brain of dementia patients from the toxic tau protein accumulation, and thereby stops the cognitive decline.
  3. Identifying dementia protective properties among existing drugs (in use in other diseases), and among herbal extracts (natural products), since such substances have the potential to become commercially available against dementia within a short time with low cost.  
  5. Enriching the fluid which bathes the brain in dementia patients with lively bioactive fluid. This novel approach may be suitable for a wide range of degenerative diseases in the nervous system, including amyotrophic lateral sclerosis (ALS).
  7. Neurogenetic aspects of neurodegenerative diseases. ​


Selected Publications
Boimel M., Grigoriadis N., Lourbopoulos A., Rozenstein L., Touloumi O., Abramsky O., Rosenmann H. Statins reduce neurofibrillary-tangle burden in a transgenic mouse model for tauopathy and Alzheimer's-disease. JNEN 68:314-25, 2009.
Lee H, Rosenmann H, Chapman J, Kingsley PB, Hoffmann C, Cohen OS, Kahana E, Korczyn AD, Prohovnik I. Thalamo-striatal diffusion reductions precede disease onset in prion mutation carriers. Brain. 132:2680-7,2009.
Shiryaev N, Jouroukhin Y, Giladi E, Polyzoidou E, Grigoriadis NC, Rosenmann H, Gozes I. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis. 34:381-8, 2009.
Dresner-Pollak R., Kinnar T., Friedlander Y., Sharon N., Rosenmann H., Pollak A. Estrogen receptor beta gene variant is associated with vascular dementia in Elderly Women. Genet Test Mol Biomarkers, 13:339-42, 2009.
Inbar D., Belinson H., Rosenmann H., Michaelson DM. The possible role of tau in mediating pathological effects of apoE4 in vivo prior to and following activation of the amyloid cascade. Neurodegener Dis. 7: 16-23, 2010
Appel S., Chapman J., Kahana E., Rosenmann H., Prohovnik I., Pras E., Reznik-Wolf H., Cohen OS. Rapidly progressive Creutzfeldt-Jakob disease in patients with Familial Mediterranean Fever. Eur J Neurol. 17:861-865, 2010.
Boimel M., Grigoriadis N., Lourbopoulos A., Haber E., Abramsky O., Rosenmann H. Efficacy and safety of immunization with phosphorylated-tau against neurofibrillary-tangles in mice. Exp. Neurol. 224: 472-485, 2010.
Miner Z., Kahana E., Baitcher F., Korczyn A., Chapman J., Cohen OS., Milo R., Aharon-Prez J., Abramsky O., Gabizon R., Rosenmann H. Tau and 14-3-3 in CSF and clinical characteristics of genetic and sporadic Creutzfeldt -Jakob disease in Israel- 1991-2006. J Neurol.258:255-262,2010.
Cohen OS., Chapman J., Lee H., Nitzan Z., Appel S., Hoffman C., Rosenmann H., Korczyn AD., Prohovnik I. Pruritus in familial Creutzfeldt - Jakob disease: A common disorder associated with Central Nervous System pathology. J Neurol. 258:89-95, 2011.
Ginsburg I., Rozenstein L., Rosenmann H. The Tibetan herbal extract P28 protects against neurotoxicity in PC12 cells. Phytother Res. 25:740-743, 2011.
Cohen OS., Prohovnik I., Korczyn AD., Ephraty L., Nitzan Z., Tsabari R., Appel S., Rosenmann H., Kahana E., Chapman J.The CJD Neurological Scale: A New Quantitative Tool for Evaluation of CJD Patients Acta Neurol Scand 124:368-74, 2011.
Lahiani I., Haber EP., Lourbopoulos A., Rozenstein L., Abramsky O., Grigoriadis N., Rosenmann H. Moderate environmental enrichment mitigates tauopathy via BDNF in a tangle-mouse model. JNEN 70:610-621, 2011.
Rosenmann H. Cerebrospinal fluid biomarkers for amyloid and tau pathology in Alzheimer's disease J Mol Neurosci, 2011 (10.1007/s12031-011-9665-5).
Meiner Z., Rosenmann H. Biological Marker in the diagnosis of dementia and Alzheimer's disease. Harefuah (Hebrew). 151(5):289-93, 318, 2012.
Cohen OS., Prohovnik I., Korczyn AD., Inzelberg R., Nitzan Z., Appel S., Kahana E., Rosenmann H., Chapman J. Characterization of Movement Disorders in Patients with Familial Creutzfeldt-Jakob Disease (f-CJD) carrying the E200K Mutation Isr Med Assoc J. 14(3):162-5, 2012.
Lee H, Rosenmann H, Chapman J, Kingsley PB, Hoffmann C, Cohen OS, Kahana E, Korczyn AD, Prohovnik I. Cerebral White Matter Disruption in Creutzfeldt-Jakob Disease. AJNR Am J Neuroradiol.2012 May 10.
Mochel F, Raphael Schiffmann R, Steenweg ME, Wallace M, Sedel F, Laforêt P, Levy R, Powers JM, Demeret P, Maisonobe T, Froissart R, Da Nobrega BB, Fogel BL, Marvin R. Natowitz MR, Lubetzki C, Durr A, Brice A, Rosenmann H, Barash V, Kahlhon O, Gomori JM, van der Knaap MS, Lossos A. Adult Polyglucosan Body Disease: Natural History and Key MRI Finding Ann Neurol. 72(3):433-41, 2012.
Rosenmann H, Blum D, Kayed R, Ittner LM. Tau protein: function and pathology. Int J Alzheimers Dis. 2012;2012:707482.
Rosenmann H. Immunotherapy for targeting tau pathology in Alzheimer’s diseases and tauopathies Curr Alzheimer Res. 1;10:217-28, 2013.
Mattsson N, Andreasson U, Persson S, Carrillo MC , Collins S, Chalbot S, Cutler N , Dufour-Rainfray D, Fagan A, Heegaard N, Hsiung GYR, Hyma B, Iqbal K, Lachno DR, Lleó A , Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JO, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, on behalf of the Alzheimer’s Association QC program work group. CSF biomarker variability in the Alzheimer’s Association quality control program Alzheimers Dement. 9:251-61,2013
Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, Nousiopoulou E, Kassis I, Abramsky O, Karussis D, Rosenmann H. Repeated immunization of mice with phos-tau causes neuroinflammation. doi:pii: S0014-4886(13)00216-1. 10.1016/j.expneurol.2013.07.006).
Rosenmann H, Meiner Z. Frontotemporal dementia: Clinical features, genetic, pathogenesis and treatment. Harefuah, 152(11) 661-666, 2013.
Gotkine M, Rozenstein L, Einstein O, Abramsky O, Argov Z, Rosenmann H. Pre-symptomatic treatment with acetylcholinesterase antisense oligonucleotides prolong survival in ALS (G93A-SOD1) mice BioMed Res It/ 2013;2013:845345. doi: 10.1155/2013/845345.
Rosenmann H. Asparagine endopeptidase cleaves tau and promotes neurodegeneration, Nature Medicine, News & Views, 20:1236-1238,2014.
Appel S, Chapman J, Cohen OS, Rosenmann H, Nitsan Z, Blatt I. Seizures in E200K familial and sporadic Creutzfeldt-Jakob disease.Acta Neurol Scand. 2014 Oct 16. doi: 10.1111/ane.12304
Rozenstein-Tsalkovich L, Kahana E, Shenker A, Baitcher F, Cohen OS, Kahana-Merhavi S, Chapman J, Korczyn AD, Aharon-Perez J, Milo R, Rosenberg A, Treves T, Wertman E, Abramsky O, Meiner Z, Rosenmann H. CSF Tau protein in Alzheimer's disease and other neurological and psychiatric diseases. Austin Alzheimer’s and Parkinson’s Disease 2014;1(2): 10.
Cohen OS, Chapman J, Korczyn AD, Warman-Alaluf N, Orlev Y, Givaty G, Nitsan Z, Appel S, Rosenmann H, Kahana E, Shechter-Amir D Characterization of sleep disorders in patients with E200K familial Creutzfeldt-Jakob disease. J Neurol. 2015 Feb;262(2):443-50. doi: 10.1007/s00415-014-7593-3
Jiang T, Chang RC, Rosenmann H, Yu JT. Advances in Alzheimer's disease: from bench to bedside.. Biomed Res Int. 2015;2015:202676. doi: 10.1155/2015/202676
Akman HO, Kakhlon O, Coku J, Peverelli L, Rosenmann H, Rozenstein-Tsalkovich L, Turnbull J, Meiner V, Chama L, Lerer I, Shpitzen S, Leitersdorf E, Paradas C, Wallace M, Schiffmann R, DiMauro S, Lossos A, Minassian BA.Deep intronic GBE1 mutation in manifesting heterozygous patients with adult polyglucosan body disease. JAMA Neurol. 2015 Apr;72(4):441-5. doi: 10.1001/jamaneurol.2014.4496
Tsalkovich L, Sallon S, Paavilainen H, Rosenmann H. Anti Alzheimer’s Disease Related Activities of Israeli Medicinal Plants. JSM Alzheimer’s Dis Related Dementia 2015 2(1): 1015.
Cohen OS, Chapman J, Korczyn AD, Nitsan Z, Appel S, Hoffmann C, Rosenmann H, Kahana E, Lee H. Familial Creutzfeldt-Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD. J Neurol. 2015 Mar;262(3):604-13. doi: 10.1007/s00415-014-7615-1
Cohen OS, Chapman J, Korczyn AD, Warman-Alaluf N, Nitsan Z, Appel S, Kahana E, Rosenmann H. CSF tau correlates with CJD disease severity and cognitive decline. Acta Neurol Scand. 2015 May 25. doi: 10.1111/ane.12441.
Hellmann MA, Kakhlon O, Landau EH, Sadeh M, Giladi N, Schlesinger I, Kidron D, Abramsky O, Reches A, Argov Z, Rabey JM, Chapman J, Rosenmann H, Gal A, Moshe Gomori J, Meiner V, Lossos A. Frequent misdiagnosis of adult polyglucosan body disease. J Neurol. 2015 Jul 21. [Epub ahead of print] 
website by Bynet Software Systems